Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

References

• WHO coronavirus (COVID-19) dashboard [Internet]. [accessed 2021 Sep 10]. https://covid19.who.int/
   Google Scholar
• Copper FA, de Vázquez CC, Bell A, Mayigane LN, Vedrasco L, Chungong S, de Vázquez CC. Preparing for COVID-19 vaccine roll-out through simulation exercises. Lancet Glob Health. 2021; 9(6):e742–10. doi:10.1016/S2214-109X(21)00051-6.
   PubMed Web of Science ®Google Scholar
• Burki TK. Challenges in the rollout of COVID-19 vaccines worldwide. Lancet Respir Med. 2021;9(4):e42–3. doi:10.1016/S2213-2600(21)00129-6.
   PubMed Web of Science ®Google Scholar
• Criteria for COVID-19 vaccine prioritization [Internet]. [accessed 2021 Sep 10]. https://www.who.int/publications/m/item/criteria-for-covid-19-vaccine-prioritization
   Google Scholar
• Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021;538:226–30. doi:10.1016/j.bbrc.2020.10.069.
   PubMed Web of Science ®Google Scholar
• Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69:379–88. doi:10.33549/physiolres.934492.
   PubMed Web of Science ®Google Scholar
• Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali MH, Sadat Larijani M, Afzali N, Ramezani A. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021;40(8):1713–19. doi:10.1007/s10096-021-04221-6.
   PubMed Web of Science ®Google Scholar
• Murchu EO, Byrne P, Carty PG, De Gascun C, Keogan M, O’-Neill M, Harrington P, Ryan M. Quantifying the risk of SARS-CoV-2 reinfection over time. Rev Med Virol. 2021:e2260. doi:10.1002/rmv.2260.
   PubMed Web of Science ®Google Scholar
• Giurgea LT, Memoli MJ. Navigating the Quagmire: Comparison and interpretation of COVID-19 vaccine phase 1/2 clinical trials. Vaccines (Basel) 2020;8(4):746 doi:10.3390/vaccines8040746.
   Web of Science ®Google Scholar
• Xing K, Tu X-Y, Liu M, Liang Z-W, Chen J-N, Li J-J, Jiang L-G, Xing F-Q, Jiang Y. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:221–28.
   PubMedGoogle Scholar
• Yan Z-P, Yang M, Lai C-L. COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals. 2021;14(5):406. doi:10.3390/ph14050406.
   Web of Science ®Google Scholar
• Sagili Anthony DP, Sivakumar K, Venugopal P, Sriram DK, George M. Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges. Clin Drug Investig. 2021;41(6):499–509. doi:10.1007/s40261-021-01022-9.
   PubMed Web of Science ®Google Scholar
• Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156–75. doi:10.2522/ptj.20070147.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4.
   PubMedGoogle Scholar
• Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimerʻs disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232–36. doi:10.1159/000051263.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–35. doi:10.1056/NEJMoa2034201.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE et al. Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G et al. Safety and immunogenicity of ChAdox1 nCov-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–93. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, Oʻ-Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–61. doi:10.1056/NEJMc2103916.
   PubMed Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82. doi:10.1056/NEJMc2032195.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–22. doi:10.1038/s41586-021-03324-6.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D et al.COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responsesNature 2020 [ accessed 2021 Jul 15]. 586(7830):594–99. doi:10.1038/s41586-020-2814-7.
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M, Salvagno GL, Peserico D, Pighi L, De Nitto S, Henry BM, Porru S, Lippi G. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. Clin Chem Lab Med. 2021;59(9):1585–91. doi:10.1515/cclm-2021-0339.
   PubMed Web of Science ®Google Scholar
• Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, Haljasmägi L, Rumm P, Maruste R, Kärner J, et al. Declined antibody responses to COVID-19 mRNA vaccine within first three months. medRxiv [Internet] 2021 [cited 2021 Jul 15]. 2021.04.19.21255714. https://www.medrxiv.org/content/full10.1101/2021.04.19.21255714v2.full
   Google Scholar
• Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140–46. doi:10.2471/blt.07.040089.
   PubMed Web of Science ®Google Scholar
• Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877–85. doi:10.1016/s0264-410x(00)00224-3.
   PubMed Web of Science ®Google Scholar
• Vaccine efficacy, effectiveness and protection [Internet]. [accessed 2021 Nov 22]. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection
   Google Scholar
• WHO issues emergency use listing for eighth COVID-19 vaccine [Internet]. [accessed 2021 Nov 22]. https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine
   Google Scholar
• Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–97. doi:10.1038/s41577-021-00526-x.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Sayedahmed EE, Elkashif A, Alhashimi M, Sambhara S, Mittal SK. Adenoviral vector-based vaccine platforms for developing the next generation of Influenza vaccines. Vaccines (Basel). 2020;8. doi:10.3390/vaccines8040574.
   PubMed Web of Science ®Google Scholar
• Bleier BS, Ramanathan M Jr, Lane AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol–head Neck Surg. 2021;164(2):305–07. doi:10.1177/0194599820982633.
   PubMed Web of Science ®Google Scholar
• Alidjinou EK, Gaillot O, Guigon A, Tinez C, Lazrek M, Bocket L, Engelmann I, Hober D. SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies. Diagn Microbiol Infect Dis. 2022;102(1):115565. doi:10.1016/j.diagmicrobio.2021.115565.
   PubMed Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–80. doi:10.1038/s41586-021-03777-9.
   PubMed Web of Science ®Google Scholar
• Noh JY, Jeong HW, Kim JH, Shin E-C. T cell-oriented strategies for controlling the COVID-19 pandemic. Nat Rev Immunol. 2021;21(11):687–88. doi:10.1038/s41577-021-00625-9.
   PubMed Web of Science ®Google Scholar
• Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27(7):1280–89. doi:10.1038/s41591-021-01386-7.
   PubMed Web of Science ®Google Scholar